This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.


  Mobile version   RSS   Subscribe   Unsubscribe   Archive   Media Kit Mar. 15, 2012

   Home   Mission/Vision    Membership    Corporate Membership    CME/CEU    JMCM    Contact Us

Click Here to view the Journal of Managed Care Medicine

Online CME/CEU Programs
Multiple Myeloma: An Update on Diagnostic and Treatment Strategies

Advanced Treatment of Osteoporosis in Postmenopausal Women

Decreasing the Cost Burden of Fibromyalgia with Early Diagnosis and Management


Announcing the NAMCP Medical Directors Lung Cancer Resource Center. Click here to visit the website.

Be sure to check out the study results of Verinata's Non-Invasive Prenatal Technology. Click here to view the press release.

Click here to check out the "Latest in Clinical Nutrition" DVD available for purchase now!

 



 Genomics

DNA finding could mean new gene therapies
UPI    Share    Share on FacebookTwitterShare on LinkedinE-mail article
U.S. scientists say they've identified a way to fix mutations in human DNA, a finding with implications for treating a host of diseases. Scientists at the UCLA stem cell center, and the departments of chemistry and biochemistry and pathology and laboratory medicine, said targeting corrective, or messenger RNAs may correct mutations in human mitochondrial DNA. More



Gene discovery gives clues to a childhood cancer
HealthDay News via U.S. News & World Report    Share    Share on FacebookTwitterShare on LinkedinE-mail article
A newly discovered genetic mutation — within the ATRX gene — is more common in teens and young adults than infants with a nerve tissue cancer called neuroblastoma. While this defect was found in many teens and young adults with neuroblastoma, none of the infants with the disease who were tested had this genetic defect. More

Spending on genetic tests to rise sharply by 2021
Los Angeles Times    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Spending on genetic tests has reached $5 billion annually and could top $25 billion within a decade, according to an insurance industry study. The rise in spending is likely to intensify the debate over genetic testing as policymakers and employers struggle to contain spiraling healthcare costs. More

 Biotech/Diagnostics/Personalized Medicine


Moving target: Why a cancer 'cure' is so elusive
ABC News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
VideoBriefEven today the prospect of a cure for most kinds cancer is elusive. Doctors have had some success using drugs like Herceptin, which tailor a patient's treatment to their specific genetic makeup. But the cancers that cannot be treated with these personalized approaches are so complex that any simple approach to treating them remains elusive, at least for now. More


Introducing mySentry™ from Medtronic...

The world’s first remote glucose monitor designed to provide protection from overnight hypoglycemia. MORE
Our activities touch many lives
AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company. We discover, develop, manufacture and market prescription medicines for cancer, cardiovascular, gastrointestinal and infection. MORE


 Regenerative Medicine


Scientists transform gut cells into insulin factories
Bioscience Technology    Share    Share on FacebookTwitterShare on LinkedinE-mail article
A study by Columbia researchers suggests that cells in the patient's intestine could be coaxed into making insulin, circumventing the need for a stem cell transplant. Until now, stem cell transplants have been seen by many researchers as the ideal way to replace cells lost in type I diabetes and to free patients from insulin injections. More



Stem cells might help transplant patients
Minneapolis Star Tribune    Share    Share on FacebookTwitterShare on LinkedinE-mail article
A new study suggests patients receiving an organ that's less than a perfect match can be protected against rejection by a second transplant — this time of the organ donor's imperfectly matched stem cells. The study is being hailed as a potential game-changer in the field of transplantation that could offer hope to patients who await or have received donor kidneys and depend on a harsh regimen of daily anti-rejection pills. More

 Emerging Medical Technologies


Chicago hospital doctors say iPads raise their efficiency
Reuters    Share    Share on FacebookTwitterShare on LinkedinE-mail article
When doctors-in-training at the University of Chicago were given iPad tablet computers to use on their rounds, they found using the device helped them be more efficient at ordering tests and procedures for their patients. The study from the university program tracked 115 residents who received devices purchased by the hospital. More

Study: Metal-on-metal hip implants 'likely to fail'
Bloomberg News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Metal-on-metal hip implants are more likely to fail than devices made from other materials and should be banned, U.K. researchers said after reviewing the world's largest database on hip replacements. More than 500,000 U.S. patients and 40,000 in the U.K. have metal-on-metal hips and are at higher risk of device failure, according to the analysis. More

US pushes healthcare providers to share records electronically
Los Angeles Times    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Hospitals and doctors have received billions of dollars in government subsidies to upgrade electronic health records, but they have not done enough to make those records shareable, a federal health official said. The national coordinator for information technology at the Department of Health and Human Services, said the government is proposing medical providers have the capability for exchanging patient data by 2014. More

 Managed Healthcare News


New insurance marketplace rules give insurers clout
Kaiser Health News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Insurers and other industry representatives will get to fill as many as half the seats on the governing boards for state health insurance exchanges, under final rules for the marketplaces issued by the Department of Health and Human Services. At least one seat must be reserved for a consumer representative. More

Bill to require financial transparency for all New Jersey hospitals
Healthcare Finance News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
In an effort to standardize financial transparency for nonprofit and for-profit hospitals in New Jersey, the state's Senate's Health Committee approved a bill that would require for-profits to publicly disclose the same financial information that nonprofit entities must file with the Internal Revenue Services. More

 FDA: New Treatments and Technology


Antipsychotic drugs grow more popular for non-mentally ill patients
The Washington Post    Share    Share on FacebookTwitterShare on LinkedinE-mail article
These days atypical antipsychotics are being prescribed by psychiatrists and primary-care doctors to treat a panoply of conditions for which they have not been approved, including anxiety, attention-deficit disorder, sleep difficulties, behavioral problems in toddlers and dementia. These new drugs account for more than 90 percent of the market and have eclipsed an older generation of antipsychotics. More

Pfizer ends Celebrex post-approval safety study
The Associated Press via CBS News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
Pfizer said it is ending a safety study of its pain drug Celebrex because of difficulty finding patients. The trial was designed to measure the effects of Celebrex on patients who were taking the drug to treat juvenile idiopathic arthritis. Pfizer said it was having trouble enrolling patients in the trial, and the study was not likely to produce meaningful results. More

FAST FACTS
"The cause of juvenile arthritis is unknown. Symptoms can exhibit in children as early as 6 months old, according to the National Institutes of Health."
 
Genomics Biotech and Emerging Medical Technologies Institute eBrief
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Christine Kraly, Content Editor, 469.420.2685   
Contribute news

This edition of the Genomics Biotech and Emerging Medical Technologies Institute eBrief was sent to %%emailaddr%%. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!
Recent issues
March 8, 2012
March 1, 2012
Feb. 23, 2012
Feb. 16, 2012



7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063